Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investors. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSmith & Nephew Regulatory News (SN.)

Share Price Information for Smith & Nephew (SN.)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,007.00
Bid: 1,005.50
Ask: 1,008.00
Change: -36.50 (-3.50%)
Spread: 2.50 (0.249%)
Open: 1,015.50
High: 1,016.00
Low: 1,005.00
Prev. Close: 1,043.50
SN. Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Statement

1 Oct 2020 07:00

RNS Number : 6885A
Smith & Nephew Plc
01 October 2020
 

 

 

 

Smith+Nephew update on third quarter trading

1 October 2020

 

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces that it expects a third quarter underlying1 revenue decline of approximately -4%.

 

All three franchises showed significant recovery following an overall underlying revenue decline of -29.3% for the second quarter. The improvement was strongest in our Orthopaedics franchise, as global levels of elective surgery continued to recover. Monthly Group growth rates were broadly stable through the quarter, with some seasonality and monthly variation across both franchises and regions, reflecting the continuing impact of COVID-19.

 

Throughout the year, we have been serving our customers, maintaining R&D, continuing with acquisitions, and launching new products, while managing our cost base and protecting employees and their jobs.

 

Further detail of the quarter, including franchise and regional sales performance, will be provided with our third quarter trading report on 29 October 2020.

 

 

- ends -

 

Enquiries

 

Investors

 

Andrew Swift

+44 (0) 1923 477433

Smith+Nephew

 

 

 

Media

 

Charles Reynolds

+44 (0) 1923 477314

Smith+Nephew

 

 

 

Susan Gilchrist / Ayesha Bharmal

+44 (0) 20 7404 5959

Brunswick

 

 

 

 

 

Notes

 

1. Unless otherwise specified as 'reported' all revenue growth throughout this document is 'underlying' after adjusting for the effects of currency translation and including the comparative impact of acquisitions and excluding disposals. All percentages compare to the equivalent 2019 period.

'Underlying revenue growth' reconciles to reported revenue growth, the most directly comparable financial measure calculated in accordance with IFRS, by making two adjustments, the 'constant currency exchange effect' and the 'acquisitions and disposals effect', described below.

The 'constant currency exchange effect' is a measure of the increase/decrease in revenue resulting from currency movements on non-US Dollar sales and is measured as the difference between: 1) the increase/decrease in the current year revenue translated into US Dollars at the current year average exchange rate and the prior revenue translated at the prior year rate; and 2) the increase/decrease being measured by translating current and prior year revenues into US Dollars using the prior year closing rate.

 

The 'acquisitions and disposals effect' is the measure of the impact on revenue from newly acquired material business combinations and recent material business disposals. This is calculated by comparing the current year, constant currency actual revenue (which includes acquisitions and excludes disposals from the relevant date of completion) with prior year, constant currency actual revenue, adjusted to include the results of acquisitions and exclude disposals for the commensurate period in the prior year. These sales are separately tracked in the Group's internal reporting systems and are readily identifiable.

 

About Smith+Nephew

 

Smith+Nephew is a portfolio medical technology business that exists to restore people's bodies and their self-belief by using technology to take the limits off living. We call this purpose 'Life Unlimited'. Our 17,500+ employees deliver this mission every day, making a difference to patients' lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global franchises of Orthopaedics, Advanced Wound Management and Sports Medicine & ENT.

 

Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $5.1 billion in 2019. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms 'Group' and 'Smith+Nephew' are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.

 

For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on TwitterLinkedIn, Instagram or Facebook.

 

  

Forward-looking Statements

 

This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: risks related to the impact of COVID-19, such as the depth and longevity of its impact, government actions and other restrictive measures taken in response, material delays and cancellations of elective procedures, reduced procedure capacity at medical facilities, restricted access for sales representatives to medical facilities, or our ability to execute business continuity plans as a result of COVID-19; economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers (including, without limitation, as a result of COVID-19); price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers (including, without limitation, as a result of COVID-19); competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations.

 

 

Trademark of Smith+Nephew. Certain marks registered US Patent and Trademark Office.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTVBLFXBKLZBBV
Date   Source Headline
28th Mar 20247:00 amRNSDirectorate Change
14th Mar 20247:00 amRNSSMITH+NEPHEW PRICES USD BOND ISSUE
13th Mar 20244:03 pmRNSDirector/PDMR Shareholding
11th Mar 20246:20 pmRNSDirector/PDMR Shareholding
11th Mar 20242:41 pmRNSAnnual Financial Report
1st Mar 202411:26 amRNSTotal Voting Rights
27th Feb 20247:00 amRNSFinal Results
23rd Feb 20247:00 amRNSChange in Director Details
14th Feb 20241:47 pmRNSBlock listing Interim Review
1st Feb 20242:12 pmRNSTotal Voting Rights
30th Jan 20247:00 amRNSNotice of Results
17th Jan 20243:05 pmRNSDirector/PDMR Shareholding
10th Jan 20247:00 amRNSAcquisition
4th Jan 202410:02 amRNSDirectorate Change
2nd Jan 202411:32 amRNSTotal Voting Rights
22nd Dec 202310:36 amRNSDirector/PDMR Shareholding
6th Dec 20237:00 amRNSDirectorate Change
1st Dec 202311:27 amRNSTotal Voting Rights
29th Nov 20237:00 amRNSMeet the Management Event
22nd Nov 20237:00 amRNSAcquisition
14th Nov 20233:25 pmRNSDirector/PDMR Shareholding
10th Nov 20233:30 pmRNSDirector/PDMR Shareholding
10th Nov 202312:56 pmRNSDirector/PDMR Shareholding
9th Nov 20235:03 pmRNSDirector/PDMR Shareholding
3rd Nov 20232:30 pmRNSDirector/PDMR Shareholding
2nd Nov 20237:01 amRNSAppointment of John Rogers as CFO
2nd Nov 20237:00 amRNS3rd Quarter 2023 Trading Report
1st Nov 20234:36 pmRNSTotal Voting Rights
1st Nov 202310:09 amRNSMEET THE MANAGEMENT EVENT
20th Oct 202310:34 amRNSSTERLING AMOUNT OF DIVIDEND
13th Oct 20238:58 amRNSNotice of Results
2nd Oct 20234:29 pmRNSTotal Voting Rights
14th Sep 20237:00 amRNSBoard Changes
1st Sep 20233:47 pmRNSTotal Voting Rights
23rd Aug 20233:41 pmRNSDirector/PDMR Shareholding
15th Aug 202311:59 amRNSDirector/PDMR Shareholding
14th Aug 20232:27 pmRNSDirector/PDMR Shareholding
7th Aug 202310:51 amRNSBlock listing Interim Review
3rd Aug 20237:02 amRNSDirectorate Change
3rd Aug 20237:00 amRNSHalf-year Report
1st Aug 202312:37 pmRNSTotal Voting Rights
21st Jul 20231:45 pmRNSDirector/PDMR Shareholding
6th Jul 20237:00 amRNSNotice of Results
3rd Jul 20234:07 pmRNSTotal Voting Rights
30th Jun 202310:21 amRNSDirector Declaration
1st Jun 202312:30 pmRNSTotal Voting Rights
24th May 20234:45 pmRNSDirector/PDMR Shareholding
19th May 20234:15 pmRNSDirector/PDMR Shareholding
5th May 20237:08 amRNSDividend Declaration
5th May 20237:00 amRNSDirector Declaration

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.